ArticleEye (London, England)2013
Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome.
Article in Eye (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Analysis of genetically determined gene expression suggests role of inflammatory processes in exfoliation syndrome.BMC genomics · 2023Pooled it
- Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study.BMC ophthalmology · 2025Article
- Metabolomic Signatures and Predictive Utility ofMetabolites · 2025Article
- Prediagnostic Plasma Metabolomic Profiles Using NMR for Exfoliation Glaucoma Among US Health Professionals.Metabolites · 2025Article
- Hematological inflammation biomarkers in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.International journal of ophthalmology · 2025Article
- Investigation of Risk Factors Predicting Cataract Surgery Complications in Patients with Pseudoexfoliation Syndrome: A Systematic Review.Journal of clinical medicine · 2024Review
- Can the Pan-Immune Inflammation Value, Systemic Inflammatory Response Index, and Other Hematological Inflammatory Indices Be Clinically Used to Predict Pseudoexfoliation?Journal of clinical practice and research · 2024Article
- Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma.Investigative ophthalmology & visual science · 2022Article
- Neutrophil lymphocyte ratio as a predictor of perioperative complications in patients with PEX Syndrome during cataract surgery.International ophthalmology · 2022Article
- Atherogenic indices in pseudoexfoliation syndrome.Eye (London, England) · 2019Article
- YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome.Eye (London, England) · 2019Article
- Elevated levels of plasma tumor necrosis factor alpha in patients with pseudoexfoliation glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Chosen Vascular Risk Markers in Pseudoexfoliation Syndrome: An Age-Related Disorder.Journal of ophthalmology · 2017Article
- Plasma adropin level in patients with pseudoexfoliation.International ophthalmology · 2016Article
- Elevated neutrophil-to-lymphocyte ratio in pseudoexfoliation syndrome.Eye (London, England) · 2016Article
- Pseudoexfoliation syndrome and cardiovascular diseases.World journal of cardiology · 2014Review
- Cardiovascular repercussions of the pseudoexfoliation syndrome.North American journal of medical sciences · 2013Review
- Machine Learning on Prediagnostic Metabolite Data Identifies Etiologic Endotypes of Exfoliation Glaucoma in United States Health Professionals.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate serum levels of YKL-40 in patients with pseudoexfoliation syndrome (PEX) in comparison with those of age- and sex-matched healthy subjects.
methodsForty patients with PEX (PEX group) and 40 age- and sex-matched control subjects (control group) were enrolled in the study. An enzyme immunoassay method using the commercially available test MicroVue YKL-40 was used to measure serum YKL-40 concentration. Systolic and diastolic blood pressures, serum levels of high sensitivity C-reactive protein (hsCRP), total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides were also examined.
resultsThe mean age was 54.4±7.6 (ranging 41-65) years in each group. The mean serum YKL-40 level of the PEX group was significantly higher than that of the control group (P<0.001). In addition, the mean serum HsCRP, total cholesterol, LDL, and triglycerides levels were significantly higher, and mean serum HDL level was significantly lower in the PEX group than in the control group (all P<0.001, excluding both P=0.002 for triglycerides and HDL levels). Further, the mean systolic and diastolic blood pressures were significantly higher in the PEX group than in the control group (P₁=0.001 and P₂=0.01, respectively).
conclusionWe have shown a relationship between PEX and elevated serum levels of YKL-40. We imply that a better understanding of the role of YKL-40 in the pathogenesis of endothelial dysfunction and atherosclerosis is necessary to develop new therapies for preventing or treating PEX. Further studies are warranted to clarify the clinical relevance of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.